RxDoctor Payments Data

Annaliese Jordan

Family · Fort Collins, CONPI 1760674246

Payments from drug & device makers

$2,882in general payments, 2019–2025

Across 36 payments — averaging $80.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$125
  • E.r. Squibb & Sons, L.L.C.$122
  • Biotronik Inc.$91
  • Pfizer$79
  • Boston Scientific$34
  • plus $24 from 2 others

What the payments were for

  • Travel & lodging$1,16741%
  • Food & beverage$1,71459%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,882 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$13,862
Medicare patients
117
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$527,208
EliquisApixaban50$62,691
JardianceEmpagliflozin37$49,118
EntrestoSacubitril/Valsartan27$38,223
Bumetanide52$3,876
Metoprolol Succinate136$2,056
Potassium Chloride40$1,277
Spironolactone79$611
ClopidogrelClopidogrel Bisulfate34$474
Furosemide86$436
Losartan Potassium59$427
Carvedilol32$356
Atorvastatin Calcium45$325
Rosuvastatin Calcium20$261
Amiodarone Hcl24$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$79$589,89972 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.

Other family in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →